# Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.

> **NCT03283384** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Borstkanker Onderzoek Groep** · enrollment: 100 (estimated)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Letrozole
- **DRUG:** Chemotherapy
- **DRUG:** Ribociclib plus letrozole

## Key facts

- **NCT ID:** NCT03283384
- **Lead sponsor:** Borstkanker Onderzoek Groep
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-15
- **Primary completion:** 2022-12-06
- **Final completion:** 2027-08
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03283384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03283384, "Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03283384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*